Most of us have had a broken bone at some point in our lives and we can all agree that it is not a pleasant feeling. Our skeletal system, though not fragile, is susceptible to an occasional crack or a full-blown broken bone.
Tessa Therapeutics, an international clinical stage biopharmaceutical company focusing on T cell therapy for solid tumors, announced the completion of a USD 80 million financing round led by Temasek, an investment company headquartered in Singapore, and joined by EDBI, Karst Peak Capital, Heliconia, Heritas and other investors.
Background Being unmarried is associated with decreased survival in the general population. Whether married, divorced, separated, widowed, or never‐married status affects outcomes in patients with cardiovascular disease has not been well characterized.
There's no shortage of info (and misinformation) out there about when to get pregnant - or when not to. But no matter what your search engine, great aunt, or the random lady standing next to you in line for coffee says, there's no magical right time. However, there are plenty of factors that may offer a sneak peek into the type of pregnancy you'll have. How old you are? Yep, that's definitely one of them.
Medical devices are increasingly the targets of cyber thieves looking to get their hands on sensitive information. And the risks are growing rapidly.
Imagine taking a pill with an ingestible sensor that takes measurements and sends information wirelessly to your doctor, or a pill that senses changes in your gut microbiome and adjusts its dose accordingly. Ingestible medical devices promise such applications, and many more, but a big challenge is making their power sources safe for our bodies.
Digital health broke out in 2017. We saw more investment than ever before: Over $4.7 billion flowed into a record number of companies. While these record-breaking investments underscore the enthusiasm for new digital health solutions, another revolution was quietly happening just outside the spotlight.
AbbVie’s investigational JAK1-inhibitor upadacitinib yielded positive top-line results in a Phase III trial as a monotherapy for rheumatoid arthritis patients. But the drug shows that it is still plagued by some safety concerns.
XELJANZ/XELJANZ XR, THE FIRST ORAL JAK INHIBITOR IN THE U.S. FOR ADULTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS, IS NOW APPROVED FOR ADULTS WITH ACTIVE PSORIATIC ARTHRITIS
A triple-drug focused remedy method may provide an efficient new treatment choice for power lymphocytic leukemia (CLL) that reduces the chance for the lengthy-time period unintended effects skilled with chemotherapy and is given for a restricted time, not as a day by day lifetime drug remedy.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.